MichaelDHogartyMD
Pediatric Hematology & Oncology • Philadelphia, PAAssociate Professor, Pediatrics, Perelman School of Medicine
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3401& Civic Center Blvd
Children's Hospital Of Philadelphia - Hem/Onc
Philadelphia, PA 19104Phone+1 215-590-3535Fax+1 215-590-3992
Summary
- Dr. Michael Hogarty, MD is a pediatric hematologist/oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, Illinois, and Illinois. He is an Associate Professor at Perelman School of Medicine.
Education & Training
Columbia University Vagelos College of Physicians and SurgeonsClass of 1990
Certifications & Licensure
PA State Medical License 1994 - 2026
IL State Medical License 1990 - 1996- IL State Medical License 1990 - 1996
American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 1 citationsOutcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology...Julie Voeller, Howard M Katzenstein, Arlene Naranjo, Sheena C Tenney, Lulu Chen
Pediatric Blood & Cancer. 2025-01-01 - Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.Erin G Brown, E Stanton Adkins, Peter Mattei, Fredric A Hoffer, Sandra L Wootton-Gorges
Journal of Pediatric Surgery. 2025-01-01 - Improvements in Children's Oncology Group neuroblastoma risk stratification through a change in age cut-off and use of INRGSS.Wendy B London, Hannah Bousquet, Meredith S Irwin, Michael D Hogarty, Susan L Cohn
Translational Pediatrics. 2024-10-01
Press Mentions
- CHOP Researchers Uncover Unique Mechanism for Cancer Therapy ResistanceApril 1st, 2022
- Panbela Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialJanuary 23rd, 2024
Grant Support
- Mechanistic biomarkers to enable Bcl2 inhibitor therapies for neuroblastomaCHILDREN'S HOSP OF PHILADELPHIA2021–2026
- Mechanistic biomarkers to enable Bcl2 inhibitor therapies for neuroblastomaCHILDREN'S HOSP OF PHILADELPHIA2021–2026
